Deutsche Bank analyst David Hoang downgraded Avadel Pharmaceuticals (AVDL) to Hold from Buy with a $20 price target after the company entered into a definitive agreement to be acquired by Alkermes (ALKS) in an all-cash transaction for up to $20.00 per share – $18.50 per share plus a contingent value right of $1.50 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- LendingClub upgraded, Enphase Energy downgraded: Wall Street’s top analyst calls
- Avadel downgraded to Neutral from Buy at H.C. Wainwright
- Avadel downgraded to Market Perform from Outperform at Leerink
- Alkermes price target raised to $45 from $38 at Piper Sandler
- Alkermes price target raised to $47 from $45 at RBC Capital